New drug combo aims to stop kidney cancer from coming back
NCT ID NCT05738694
Summary
This study is testing whether giving two cancer drugs (axitinib and a PD-1 antibody) before surgery can help stop kidney cancer from returning. It will involve 298 patients with high-risk kidney cancer who are scheduled for surgery. Patients will be randomly assigned to receive either the drug combination plus surgery or surgery alone to see which approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, China
Contact
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact
-
Fudan University Cancer Hospital
RECRUITINGShanghai, China
Contact
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact
-
The First Affiliated Hospital of Zhengzhou Hospital
RECRUITINGZhengzhou, China
Contact
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, China
Contact
-
West China Hospital
RECRUITINGSichuan, China
Contact
Conditions
Explore the condition pages connected to this study.